News for XORTX Therapeutics Inc. (XRX.CN)

Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. ( CSCI; TSX: CSCI) today announced that it has e

XORTX Therapeutics (XRTX) has revealed plans for a non-brokered private placement aiming to gather up to $3 million. This initiative will involve the issuance o

Ӣ XORTX Therapeutics (XRTX) announces $3 million non-brokered private placement. Ӣ Funds to be utilized for advancing gout treatment programs. Ӣ Offering

Ӣ Proceeds will be used to advance XORTX's programs for gout Ӣ CALGARY, Alberta, May 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (

XORTX Therapeutics, trading under the ticker XRTX, has successfully obtained feedback from the U.S. Food and Drug Administration (FDA), outlining the essential

● XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc

XORTX Therapeutics (XRTX) secures European patent for 'Xanthine Oxidase Inhibitor Formulations'. The patent broadens IP protection for gout and ADPKD tr

Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc

XORTX Therapeutics is currently under pressure to meet Nasdaq's minimum bid price requirement. Analysts remain optimistic about the stock with a one-yea

**media[598589]**

● Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX

**media[548320]**

Significant Transaction by ARMISTICE CAPITAL, LLC (Trades, Portfolio) On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a noteworthy tra

XORTX Announces Change of Auditor

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing

**media[490639]**

**media[440958]**

Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism

CALGARY, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) —  XORTX Therapeutics Inc. (“